•
Dec 31, 2023

Bio-Techne Q2 2024 Earnings Report

Bio-Techne's Q2 2024 earnings were released, revealing a slight revenue increase and mixed segment performance amid challenging macroeconomic conditions.

Key Takeaways

Bio-Techne reported flat revenue growth in the second quarter of fiscal year 2024, with organic revenue declining by 2%. GAAP EPS was $0.17, while adjusted EPS was $0.40. The company faced headwinds from BioPharma macroeconomic conditions but saw strength in the academic end market and growth in instrument consumables.

Organic revenue declined by 2% to $272.6 million.

GAAP EPS was $0.17, and adjusted EPS was $0.40.

Instrument consumables grew by 20%, offsetting BioPharma headwinds.

Cash flow from operations increased by 18% to $142.5 million.

Total Revenue
$273M
Previous year: $272M
+0.4%
EPS
$0.4
Previous year: $0.47
-14.9%
Organic sales growth
-2%
Previous year: 4%
-150.0%
Gross Profit
$177M
Previous year: $183M
-3.7%
Cash and Equivalents
$130M
Previous year: $165M
-21.0%
Free Cash Flow
$68.3M
Previous year: $58.3M
+17.1%
Total Assets
$2.73B
Previous year: $2.36B
+15.5%

Bio-Techne

Bio-Techne

Bio-Techne Revenue by Segment

Revenue & Expenses

Visualization of income flow from segment revenue to net income